← Leaderboards
Xiaosong Wang
Baylor College Of Medicine
$3,641,074
Attributed
$3,641,074
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $661K · FY2014–21$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$3,641,074 · 3
By mechanism
R01$3,238,674 · 2
R21$402,400 · 1
Top collaborators
No co-investigators on record.
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Steffi Oesterreich$10,632,097
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsMolecularTumorGeneticKnock-DownCellsPhenotypeResistanceOverexpressionEventGenesCancer GenomeMalignant NeoplasmsTumor ProgressionRecurrenceEstrogen ReceptorsEstrogen Receptor PositiveGenomicsMalignant Breast NeoplasmMammary NeoplasmsDrug TargetingIn VivoMouse ModelBreast Cancer Cell
Grant awards (13)
Characterization of EPHA3 intragenic rearrangements in high-grade serous carcinoma progression and recurrence$219,491
R21 · FY2021 · CA · contact PI
Characterization of EPHA3 intragenic rearrangements in high-grade serous carcinoma progression and recurrence$182,909
R21 · FY2020 · CA · contact PI
CHARACTERIZATION OF RECURRENT ADJACENT GENE TRANSLOCATIONS IN BREAST CANCER$274,459
R01 · FY2019 · CA · contact PI
Integrative Consig: NLK as Attractive Drug Target for Intractable Breast Cancer$324,738
R01 · FY2018 · CA · contact PI
CHARACTERIZATION OF RECURRENT ADJACENT GENE TRANSLOCATIONS IN BREAST CANCER$41,789
R01 · FY2018 · CA · contact PI
Integrative Consig: NLK as Attractive Drug Target for Intractable Breast Cancer$323,008
R01 · FY2017 · CA · contact PI
CHARACTERIZATION OF RECURRENT ADJACENT GENE TRANSLOCATIONS IN BREAST CANCER$322,663
R01 · FY2017 · CA · contact PI
Integrative Consig: NLK as Attractive Drug Target for Intractable Breast Cancer$320,069
R01 · FY2016 · CA · contact PI
CHARACTERIZATION OF RECURRENT ADJACENT GENE TRANSLOCATIONS IN BREAST CANCER$319,550
R01 · FY2016 · CA · contact PI
CHARACTERIZATION OF RECURRENT ADJACENT GENE TRANSLOCATIONS IN BREAST CANCER$326,710
R01 · FY2015 · CA · contact PI
Integrative Consig: NLK as Attractive Drug Target for Intractable Breast Cancer$324,738
R01 · FY2015 · CA · contact PI
CHARACTERIZATION OF RECURRENT ADJACENT GENE TRANSLOCATIONS IN BREAST CANCER$336,212
R01 · FY2014 · CA · contact PI
Integrative Consig: NLK as Attractive Drug Target for Intractable Breast Cancer$324,738
R01 · FY2014 · CA · contact PI